Article Type
Changed
Fri, 01/04/2019 - 11:13

In an interview with Dr David Henry, Editor-in-Chief of The Journal of Community and Supportive Oncology, Dr Todd Brown reviews the several different classes of the hyperglycemic management drugs (apart from insulin) focusing on how they work and how they should be used in the management of diabetes in patients with cancer. Dr Henry is vice-chair of the Department of Medicine and Clinical Professor of Medicine at Pennsylvania Hospital, in Philadelphia, and Dr Brown is associate professor of Medicine and Epidemiology in the Division of Endocrinology, Diabetes, and Metabolism at the Johns Hopkins University in Baltimore, Maryland.

 

Listen to the podcast below, or click on the PDF icon at the top of this introduction to read a transcript of the interview.

 


Article PDF
Author and Disclosure Information

David Henry, MD, interviews Todd Brown, MD

Publications
Topics
Legacy Keywords
diabetes, bladder cancer, pancreatic cancer, insulin, sulfonylureas, metformin, hypoglycemia, cardiovascular risk, fracture risk, thiazolidinedione, TZD, liver disease, renal disease, weight gain, glitazone, GLP-1, stroke, myocardial infarction, gliptin
Sections
Author and Disclosure Information

David Henry, MD, interviews Todd Brown, MD

Author and Disclosure Information

David Henry, MD, interviews Todd Brown, MD

Article PDF
Article PDF

In an interview with Dr David Henry, Editor-in-Chief of The Journal of Community and Supportive Oncology, Dr Todd Brown reviews the several different classes of the hyperglycemic management drugs (apart from insulin) focusing on how they work and how they should be used in the management of diabetes in patients with cancer. Dr Henry is vice-chair of the Department of Medicine and Clinical Professor of Medicine at Pennsylvania Hospital, in Philadelphia, and Dr Brown is associate professor of Medicine and Epidemiology in the Division of Endocrinology, Diabetes, and Metabolism at the Johns Hopkins University in Baltimore, Maryland.

 

Listen to the podcast below, or click on the PDF icon at the top of this introduction to read a transcript of the interview.

 


In an interview with Dr David Henry, Editor-in-Chief of The Journal of Community and Supportive Oncology, Dr Todd Brown reviews the several different classes of the hyperglycemic management drugs (apart from insulin) focusing on how they work and how they should be used in the management of diabetes in patients with cancer. Dr Henry is vice-chair of the Department of Medicine and Clinical Professor of Medicine at Pennsylvania Hospital, in Philadelphia, and Dr Brown is associate professor of Medicine and Epidemiology in the Division of Endocrinology, Diabetes, and Metabolism at the Johns Hopkins University in Baltimore, Maryland.

 

Listen to the podcast below, or click on the PDF icon at the top of this introduction to read a transcript of the interview.

 


Publications
Publications
Topics
Article Type
Legacy Keywords
diabetes, bladder cancer, pancreatic cancer, insulin, sulfonylureas, metformin, hypoglycemia, cardiovascular risk, fracture risk, thiazolidinedione, TZD, liver disease, renal disease, weight gain, glitazone, GLP-1, stroke, myocardial infarction, gliptin
Legacy Keywords
diabetes, bladder cancer, pancreatic cancer, insulin, sulfonylureas, metformin, hypoglycemia, cardiovascular risk, fracture risk, thiazolidinedione, TZD, liver disease, renal disease, weight gain, glitazone, GLP-1, stroke, myocardial infarction, gliptin
Sections
Citation Override
JCSO 2016;14(7):326-330
Disallow All Ads
Alternative CME
Article PDF Media